Ghura, Shivesh
Gross, Robert
Jordan-Sciutto, Kelly
Dubroff, Jacob
Schnoll, Robert
Collman, Ronald G.
Ashare, Rebecca L.
Funding for this research was provided by:
National Institute on Drug Abuse (R01 DA042682; R01 DA044906, K24 DA045244)
National Institute of Allergy and Infectious Diseases (P30 AI045008)
National Institute of Mental Health (P30 MH097488)
Article History
Received: 3 October 2019
Accepted: 1 December 2019
First Online: 13 December 2019
Compliance with ethical standards
:
: Dr. Schnoll receives medication and placebo free of charge from Pfizer for clinical trials and has provided consultation to Pfizer, GlaxoSmithKline, and Curaleaf. Dr. Gross serves on a Pfizer Data and Safety Monitoring Board for a drug unrelated to smoking or HIV. Dr. Ashare has an investigator-initiated grant from Novo Nordisk for a drug unrelated to the current paper.